Piperacillin, a new semisynthetic penicillin, was evaluated for efficacy and safety in 26 patients, most of whom had pneumonia. Included were four patients with gram-negative meningitis in whom the penetration of piperacillin into cerebrospinal fluid was determined. Cure was achieved in 11 of 17 patients with pneumonia; another 4 were improved. One relapse and one failure occurred among nine patients with gram-negative pneumonia. Cure or improvement occurred in seven of nine patients with gram-negative infection in various extrapulmonary sites. Piperacillin given by continuous infusion in a dosage ranging from 324 to 436 mg/kg of body weight per day to four patients with meningitis resulted in a mean cerebrospinal fluid level of 23 tig/ml at 24 h; the mean penetration of piperacillin into the cerebrospinal fluid was 32% at this interval. Levels of piperacillin in cerebrospinal fluid collected later during the course of therapy were also adequate. Adverse effects were noted in six patients, but only one episode of granulocytopenia was serious. Emergence of resistance to piperacillin did not occur, and only one superinfection was noted. Piperacillin appeared to be efficacious in the treatment of pneumonia. It penetrated well into the cerebrospinal fluid of patients with meningitis and may be useful for treatment of selected gram-negative infections in extrapulmonary sites.
Piperacillin is a new semisynthetic antibiotic formed by the attachment of a piperazine derivative to aminobenzylpenicillin. This agent has a broad spectrum of activity that includes Pseudomonas aeruginosa and many species of Enterobacteriaceae. Most P. aeruginosa isolates are inhibited at concentrations of piperacillin that are considerably lower than those of carbenicillin or ticarcillin (4, 8, 11, 27) . The antibacterial spectrum of piperacillin is greater than that of other penicillins now available and includes Klebsiella pneumoniae, a species usually resistant to the other penicillin derivatives (17, 26, 29) . Piperacillin is not active against penicillinase-producing staphylococci or certain isolates of gram-negative bacilli that have acquired resistance to the other ,B-lactam antibiotics, since it is inactivated by some 8-lactamases (26) . Piperacillin can be given in sufficient quantities to achieve levels in the serum well above the concentrations needed to inhibit many bacteria that commonly cause serious infections (1) . The purpose of this study was to evaluate the efficacy t Present address: 19.30 N.E. 47th Street, SLite 208, Fort Lauderdale, Fl, 33308. and safety of piperacillin as the sole antibiotic treatment for bacterial pneumonia and for other selected infections caused by gram-negative bacteria that were susceptible to piperacillin.
MATERIALS AND METHODS
Patients included in this study were hospitalized at the Jackson Memorial Hospital in Miami, Fla. The basis for inclusion in this study was the presence of a serious infection caused by a strain that was susceptible to piperacillin. Penicillin allergy or pregnancy was a reason for exclusion. Patients who were recently treated with antibiotics active against the infecting strain were also excluded unless the infection had failed to respond to an adequate course of treatment.
Written informed consent was obtained from the patient or a responsible family member before the administration of piperacillin.
Cultures from suspected sites of infection were obtained before the administration of piperacillin. Sputum obtained either by expectoration or by tracheal suction was cultured when fewer than 10 squamous epithelial cells per low-powered field were present in a stained smear (18 Standard microbiological methods were used in the clinical microbiology laboratory to identify bacterial isolates (9, 14, 24) ; the standardized disk diffusion method was used to determine susceptibility to antibiotics other than piperacillin (2) . The minimal inhibitory concentration (MIC) of piperacillin for an isolate was determined by a broth dilution method adapted for use in a microtiter system (15) . Organisms inhibited by 50 ,ug of piperacillin per ml or less were considered, for the purpose of this study, susceptible to this agent. Serum and CSF levels of piperacillin were determiniedi by an agar plate bioassay method (1) . Serum Table  2 . The therapeutic responses in these patients with pneumonia were classified as cure in 11, improvement in 5, relapse in 1, and failure in 1. The failure occurred in a patient with hairy cell leukemia who died after receiving only two doses of piperacillin. Three patients with S. pneumoniae infection were considered improved after treatment with piperacillin. Eradication of the infecting species could not be proven in two of these, who died from other causes. Another patient inmproved after receiving piperacillin for 72 h, at which time another antibiotic was insti- The other infections that were treated with piperacillin were P. aeruginosa meningitis (three patients), meningitis due to Flavobacterium meningosepticum, acute otitis media due to P. aeruginosa (two patients), S. marcescens bacteremia, metacarpal osteomyelitis caused by P. aeruginosa, and a polymicrobial liver abscess (Table 3) . Two patients with meningitis were cured of their infection. The CSF from one patient with Pseudomonas meningitis was sterile after 24 h of treatment with piperacillin; however, organisms were cultured from the CSF of the patient cured of F. meningosepticum men- meningitis during the second and third courses of piperacillin, and a pruritic erythematous rash appeared on his extremities during the third course of piperacillin. Later courses of piperacillin were not associated with either eosinophilia or dermatitis. No biochemical abnormalities developed during treatment except for increased serum lactate dehydrogenase in one patient. There was no evidence of hematological or hepatic toxicity in that patient. Nephrotoxicity, electrolyte imbalance, or bleeding tendencies were not observed in this study. DISCUSSION Piperacillin was used successfully to cure 17 of the 26 infections included in this study. Another five patients improved while receiving piperacillin, but they failed to meet the criteria for cure, which required proof of eradication of the causative organism after the course of therapy. Relapses occurred in two patients, both of whom had Pseudomonas infections. The patient with recurrent meningitis continued to relapse, presumably because of an occult parameningeal focus of infection. The other relapse was temporally related to the development of granulocytopenia, which may have been an adverse reaction to piperacillin. Only one superinfection was noted, and that was caused by a multiply resistant gram-negative rod. There were two treatment failures in this series. One patient with fulminant Klebsiella pneumonia showed no response to treatment with piperacillin and died within 12 h. The other failure occurred in a patient who had a necrotic hepatic malignancy associated with an abscess that could not be adequately drained. Piperacillin appeared to be as efficacious as penicillin in pneumonias caused by penicillin-susceptible strains. It is likely that doses of piperacillin lower than those used in this study would have been an effective treatment for these infections, especially pneumococcal pneumonia. Piperacillin was not as efficacious against pulmonary infections caused by gram-negative bacilli as against those caused by gram-positive cocci, but our experience was encouraging. We did not encounter the development of resistance, though other investigators have reported treatment failure because of the development of resistance to piperacillin (22, 28) .
Serum concentrations of piperacillin after intermittent infusion in our patients were comparable to those in normal adults reported by Batra et al. (1) . They found that 4 g (50 to 63 mg/kg) of piperacillin given over 0.5 h yielded a mean level in the serum of 244 yg/ml at the completion of the infusion. The mean serum levels of piperacillin at 0.5 h, 1.5 h, and 4 h after the completion of infusion were 141, 72, and 15 yg/ml, respectively. The mean serum half-life of piperacillin was reported to be 60 min (1) .
High levels of piperacillin can be maintained in the serum by administering a continuous infusion in dosages ranging from 300 to 400 mg/kg per day. The concentration of piperacillin in the CSF of patients with acute meningitis was found to approach one-third of the level maintained in the serum by continuous infusion. This finding indicates that piperacillin can be administered intravenously to obtain CSF levels that exceed the MIC for most susceptible strains. Our data suggest that appreciable quantities of piperacillin continue to be present in the CSF during the resolution phase of meningitis, even though the levels are likely to decrease as the inflammatory reaction in the meninges resolves (3, 12, 19) . Shishido and Matsumoto reported that the level of piperacillin in CSF samples ranged from 1.0 to 6.7 ,ug/ml in one patient given intermittent infusions of 74 mg/kg at 6-h intervals (21) . They reported that ratios of the levels of piperacillin in CSF to those in serum ranged from 0.25 to 1.9; however, this variability can be attributed to the intermittent infusions of the drug. Data on the penetration of other penicillin antibiotics into the CSF of humans are limited. Most studies involving the use of intermittent infusion of an antibiotic appeared to have overestimated penetration. For example, Hieber and Nelson studied patients receiving penicillin intermittently and reported that during the acute phase of meningitis, the concentrations of penicillin in CSF averaged 18.4% of the levels in serum (12 (28) . Granulocytopenia has been reported with most other penicillins (6, 10, 16, 20) . This reaction appears to be related to the dose and duration of the administration of penicillin (20) . Superinfection appeared to be an infrequent occurrence, even though piperacillin has an extended spectrum of activity. A rapid emergence of resistance to piperacillin was not observed when this drug was used alone.
